Chemotherapy as initial treatment in gliomatosis cerebri: Results with temozolomide

Netta Levin*, John Moshe Gomori, Tali Siegal

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

60 Scopus citations


The optimal therapy for gliomatosis cerebri is unclear, and the rate of response to chemotherapy is not known. Eleven radiotherapy-naive patients received a median number of 10 treatment cycles of temozolomide. An objective response was documented in 45%, and the median time to tumor progression was 13 months with a progression-free survival of 55% at 12 months. These results indicate that radiotherapy to extensive brain regions can be deferred until progressive disease is observed.

Original languageAmerican English
Pages (from-to)354-356
Number of pages3
Issue number2
StatePublished - 27 Jul 2004
Externally publishedYes


Dive into the research topics of 'Chemotherapy as initial treatment in gliomatosis cerebri: Results with temozolomide'. Together they form a unique fingerprint.

Cite this